RCS - PureTech Health PLC - PRTC's Seaport Appoints Global Pharma Exec to BOD

Puretech HealthAnnouncement

13/08/2024 12:15

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240813:nRSM1606Aa&default-theme=true

RNS Number : 1606A  PureTech Health PLC  13 August 2024

13 August 2024

PureTech Health plc

 

PureTech Founded Entity Seaport Therapeutics Appoints David Wheadon, M.D., to
its Board of Directors

 

Prominent pharmaceutical leader from AstraZeneca, Abbott, GlaxoSmithKline and
Eli Lilly, brings extensive regulatory affairs and clinical development
expertise to Seaport Board

 

PureTech Health plc (https://puretechhealth.com/) (Nasdaq: PRTC, LSE: PRTC)
("PureTech" or the "Company"), a clinical-stage biotherapeutics company, noted
that its Founded Entity, Seaport Therapeutics (https://seaporttx.com/) , a
biopharmaceutical company that is advancing novel neuropsychiatric medicines
with a proven strategy and team, today announced the appointment of David
Wheadon, M.D., to its Board of Directors. Dr. Wheadon is a physician and
psychiatrist with more than three decades of experience in regulatory affairs,
clinical strategy, and global health policy at multinational companies across
the pharmaceutical industry.

 

The full text of the announcement from Seaport is as follows:

 

Seaport Therapeutics Appoints David Wheadon, M.D., to its Board of Directors

 

Prominent pharmaceutical leader from AstraZeneca, Abbott, GlaxoSmithKline and
Eli Lilly, brings extensive regulatory affairs and clinical development
expertise to Seaport Board

 

BOSTON, August 13, 2024 - Seaport Therapeutics (https://seaporttx.com/) , a
clinical-stage biopharmaceutical company that is advancing novel
neuropsychiatric medicines with a proven strategy and team, today announced
the appointment of David Wheadon, M.D., to its Board of Directors. Dr. Wheadon
is a physician and psychiatrist with more than three decades of experience in
regulatory affairs, clinical strategy, and global health policy at
multinational companies across the pharmaceutical industry.

 

"It is our pleasure to welcome David Wheadon to our Board of Directors," said
Daphne Zohar, Founder and Chief Executive Officer at Seaport. "David brings
extensive regulatory expertise, and a successful background in the development
and approval of several important neuropsychiatric medicines which will
benefit Seaport as we advance our clinical-stage pipeline of therapeutics for
the treatment of depression, anxiety and other neuropsychiatric disorders."

 

Dr. Wheadon is a distinguished pharmaceutical leader who most recently served
as Senior Vice President, Global Regulatory Affairs, Patient Safety and
Quality Assurance at AstraZeneca. While at AstraZeneca, he drove regulatory
strategy for the development and approval of the company's product portfolio
and oversaw the global regulatory affairs, patient safety and quality
assurance organization. Dr. Wheadon also served as a member of the company's
Global Medicines Development Leadership team and Late-Stage Product Committee,
which was responsible for the progression of AstraZeneca's late-stage
portfolio through clinical development, regulatory approvals and market
access.

 

"I'm excited to join the talented members of Seaport's Board and executive
team with deep experience and a proven track record of developing
neuropsychiatric drugs," said Dr. Wheadon. "Seaport has a promising pipeline
of novel antidepressants and anxiolytics, and I look forward to being a part
of the journey of delivering these important new treatments to the millions of
patients suffering from devastating and debilitating mental health conditions,
including depression and anxiety."

 

Dr. Wheadon held previous leadership positions at the Pharmaceutical Research
and Manufacturers of America (PhRMA), the Juvenile Diabetes Research
Foundation as well as senior regulatory and clinical development leader roles
at Abbott and GlaxoSmithKline. He also served on the Board of Directors at
Karuna Therapeutics until its acquisition by Bristol Myers Squibb in March
2024.  He began his career as a clinical research physician in neuroscience
at Eli Lilly. Dr. Wheadon earned an A.B. from Harvard College and an M.D. from
Johns Hopkins University School of Medicine. His residency was in psychiatry
at the Tufts-New England Medical Center. He is a member of the American
Academy of Pharmaceutical Physicians and the American Psychiatric Association.

 

"I had the privilege of working with David on the Karuna board, so I know how
incredibly fortunate we are to gain his unparalleled level of expertise and
industry perspective at Seaport," said Steve Paul, M.D., Founder and Chair of
the Board of Directors at Seaport. "He has an accomplished career and an
astute understanding of the regulatory and clinical landscape, which will make
him a valuable addition to Seaport as we continue to advance our novel
neuropsychiatric medicines through clinical development."

 

About Seaport Therapeutics

Seaport Therapeutics is a clinical-stage biopharmaceutical company advancing
the development of novel neuropsychiatric medicines in areas of high unmet
patient needs. The Company has a proven strategy of advancing clinically
validated mechanisms previously held back by limitations that are overcome
with its proprietary Glyph(TM) technology platform. All the therapeutic
candidates in its pipeline of first and best-in-class medicines are based on
the Glyph platform, which is uniquely designed to enable oral bioavailability,
bypass first-pass metabolism and reduce hepatotoxicity and other side effects.
Seaport is led by an experienced team that invented and advanced important
neuropsychiatric medicines and are guided by an extensive network of renowned
scientists, clinicians and key opinion leaders. For more information, please
visit www.seaporttx.com (http://www.seaporttx.com) .

About PureTech Health

PureTech is a clinical-stage biotherapeutics company dedicated to giving life
to new classes of medicine to change the lives of patients with devastating
diseases. The Company has created a broad and deep pipeline through its
experienced research and development team and its extensive network of
scientists, clinicians and industry leaders that is being advanced both
internally and through its Founded Entities. PureTech's R&D engine has
resulted in the development of 29 therapeutics and therapeutic candidates,
including two that have received both U.S. FDA clearance and European
marketing authorization and a third (KarXT) that has been filed for FDA
approval. A number of these programs are being advanced by PureTech or its
Founded Entities in various indications and stages of clinical development,
including registration enabling studies. All of the underlying programs and
platforms that resulted in this pipeline of therapeutic candidates were
initially identified or discovered and then advanced by the PureTech team
through key validation points.

 

For more information, visit www.puretechhealth.com
(http://www.puretechhealth.com/)  or connect with us on X (formerly Twitter)
@puretechh.

 

Cautionary Note Regarding Forward-Looking Statements

This press release contains statements that are or may be forward-looking
statements within the meaning of the Private Securities Litigation Reform Act
of 1995. All statements contained in this press release that do not relate to
matters of historical fact should be considered forward-looking statements,
including without limitation those related to Seaport's development plans for
its pipeline of therapeutics for the treatment of depression, anxiety and
other neuropsychiatric disorders, potential benefits to patients and our
future prospects, developments and strategies. The forward-looking statements
are based on current expectations and are subject to known and unknown risks,
uncertainties and other important factors that could cause actual results,
performance and achievements to differ materially from current expectations,
including, but not limited to, those risks, uncertainties and other important
factors described under the caption "Risk Factors" in our Annual Report on
Form 20-F for the year ended December 31, 2023, filed with the SEC and in our
other regulatory filings. These forward-looking statements are based on
assumptions regarding the present and future business strategies of the
Company and the environment in which it will operate in the future. Each
forward-looking statement speaks only as at the date of this press release.
Except as required by law and regulatory requirements, we disclaim any
obligation to update or revise these forward-looking statements, whether as a
result of new information, future events or otherwise.

 

Contact:

PureTech

Public Relations

publicrelations@puretechhealth.com (mailto:publicrelations@puretechhealth.com)

Investor Relations

IR@puretechhealth.com (mailto:IR@puretechhealth.com)

 

UK/EU Media

Ben Atwell, Rob Winder

+44 (0) 20 3727 1000

puretech@fticonsulting.com (mailto:puretech@fticonsulting.com)

 

US Media

Nichole Bobbyn

+1 774 278 8273

nichole@tenbridgecommunications.com
(mailto:nichole@tenbridgecommunications.com)

 

 

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NRAGPUPGRUPCGBP